NASH, the golden rush of Bio-pharma

pharmaceutical industry

[vc_row][vc_column][vc_column_text]Nowadays, we live older than before thanks to technology and medical advances. However, new diseases such as NASH are discovered. Scientists, describe NASH as the pathology of the century.

What is Non-Alcoholic SteatoHepatitis (NASH)?

Non-alcoholic SteatoHepatitis (NASH) is a damaged liver inflamed.
It’s caused by a build-up of fat in the liver. The fat can cause inflammation and damages cells in the liver which can not work as well as it should.
NASH can cause scarring of the liver, which leads to cirrhosis (stage 4)
This disease has similar impacts as long-term, heavy drinking without alcohol abuse.
Something in their environment that triggers the inflammation or it can be genetic. But there are risk factors too:

  • Obesity
  • Insulin resistance and type 2 diabetes
  • High cholesterol and high triglycerides
  • Metabolic syndrome

Diagnostics

To see if fat is building up in liver, doctor do tests such as: blood tests, abdominal ultrasound, CT /MRI scan and liver biopsy

Treatment

Nowadays there is no treatment for NASH. But some solutions are reducing the total cholesterol level:

  • Losing 3% to 10% of total body weight can make a difference
  • Control diabetes
  • Exercise regularly

The NASH Market

Seven countries are mainly concerned: USA, Canada, Japan, UK, France, Germany and Spain. In America alone, 6 million persons were affected and diagnosed in 2015 and 600 000 among them have a cirrhosis.
There are currently more than 150 studies about NAFLD and NASH and experts predict that between 2015 and 2026, people affected will increase about 40 %.
This market is estimated to 35 $ billion in 2022-2023 and 45 $ billion in 2026. There are three major candidates for the release of a treatment in 2020: Intercept, Genfit, Allergan and more than 50 other bio-pharma companies.

Why bio-pharma are interested about NASH?

Bio-pharma are focusing on the development of a treatment because the diseased concern a lot of people who have a great purchasing power (more than 1 billion todays, in the world). This is a “juicy” market.  Indeed, being the first one to release a treatment against NASH in 2020, can make them reach about 5 to 9 billion of profits per year. These profits can be explained by the cost of liver transplant: 790 000 $ in the final stage. On the other hand, NASH treatment, which prevent the stage final cost only 14 000 $. So patients and governments (aid, care) can save 776 000$.
There is also a good opportunity to be recognized. For small labs or biotechnological companies, it is a way to be known and develop a partnership with the big pharmaceutical companies. Thus they will rise money in order to expand their activity field and complete their projects. For big pharmaceutical companies it is a good opportunity to make more money and take market shares from competitors. They can penetrate new markets and new areas.
But will this market be the expected success or will it be reduced and limited to the highest stages (3 and 4)?

Conclusion

With the ageing of the population and the countries’ developing (industrial aliments), we can think NASH disease will progress along years. Fortunately, the NASH race will end very soon for both patients and bio-pharmaceutical companies’ happiness.
Moreover, if we want to limit the NASH expansion, we have to change our diet (less sugar and fat) and checking more often our health thanks to connected objects.
 
[/vc_column_text][vc_tta_accordion active_section=””][vc_tta_section title=”Références” tab_id=”1514946612328-1054cf4c-da57″][vc_column_text]

  • https://www.webmd.com/digestive-disorders/tc/nonalcoholic-steatohepatitis-nash-overview#1
  • http://www.nashbiotechs.com/analyse-des-biotechs-dans/presentation-de-la-nash/ce-que-lon-sait-sur-la-nash.html
  • http://www.centre-hepato-biliaire.org/maladies-foie/nash.html
  • http://www.slate.fr/story/103349/epidemie-cirrhose-foies-gras-sucre
  • https://medcitynews.com/2017/05/report-nash-market-increase-fortyfold-2026/

[/vc_column_text][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row]

Anthony PERUZZO


Leave a Reply

Your email address will not be published. Required fields are marked *


About us

Bonds & Shares is a participatory non-Profit information platform for, through and by experts in finance and business.


CONTACT US

CALL US ANYTIME



Latest posts



Newsletter


    Categories